Targeting ANXA3 in combination with sorafenib for the treatment of hepatocellular carcinoma

被引：0
|
作者：
Tong, Man
Luk, Steve
Che, Noelia
Ding, Jin
Lee, Terence K. W.
Ma, Stephanie
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3146
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Antibody-mediated blockade of annexin A3 (ANXA3) synergistically enhances the efficacy of sorafenib and regorafenib for hepatocellular carcinoma
    Tong, Man
    Che, Noelia
    Zhou, Lei
    Kau, Phillis W.
    Luk, Steve T.
    Chen, Xin
    Ding, Jin
    Lee, Terence K.
    Ma, Stephanie
    CANCER RESEARCH, 2018, 78 (13)
  • [2] MicroRNA-205-5p regulates the chemotherapeutic resistance of hepatocellular carcinoma cells by targeting PTEN/JNK/ANXA3 pathway
    Shao, Ping
    Qu, Wei-Kun
    Wang, Cheng-Ye
    Tian, Yu
    Ye, Ming-Liang
    Sun, De-Guang
    Sui, Ji-Dong
    Wang, Li-Ming
    Fan, Rong
    Gao, Zhen-Ming
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (09): : 4300 - 4307
  • [3] Sorafenib in Combination With Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
    Geschwind, Jean-Francois H.
    Chapiro, Julius
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (08) : 585 - 587
  • [4] Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
    Roderburg, Christoph
    Oezdirik, Burcin
    Wree, Alexander
    Demir, Muenevver
    Tacke, Frank
    HEPATIC ONCOLOGY, 2020, 7 (02)
  • [5] Sorafenib for the treatment of hepatocellular carcinoma
    Woerns, Marcus Alexander
    Galle, Peter Robert
    HEPATIC ONCOLOGY, 2014, 1 (02) : 189 - 204
  • [6] Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
    Jian-Jun Gao
    Zhen-Yan Shi
    Ju-Feng Xia
    Yoshinori Inagaki
    Wei Tang
    World Journal of Gastroenterology, 2015, (42) : 12059 - 12070
  • [7] Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
    Gao, Jian-Jun
    Shi, Zhen-Yan
    Xia, Ju-Feng
    Inagaki, Yoshinori
    Tang, Wei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (42) : 12059 - 12070
  • [8] Combination targeting of epithelial-to-mesenchymal transition and immune checkpoint molecules resensitizes hepatocellular carcinoma to sorafenib treatment
    Shrestha, R.
    Bridle, K. R.
    Crawford, D. H. G.
    Jayachandran, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 28 - 28
  • [9] LXR agonism and Sorafenib treatment as novel combination therapy for hepatocellular carcinoma
    Preziosi, Morgan E.
    Zahm, Adam M.
    Kaestner, Klaus H.
    Wangensteen, Kirk J.
    FASEB JOURNAL, 2019, 33
  • [10] The Role of PI3K/mTOR Inhibition in Combination with Sorafenib in Hepatocellular Carcinoma Treatment
    Gedaly, Roberto
    Angulo, Paul
    Chen, Changguo
    Creasy, Kate Townsend
    Spear, Brett T.
    Hundley, Jonathan
    Daily, Michael F.
    Shah, Malay
    Evers, B. Mark
    ANTICANCER RESEARCH, 2012, 32 (07) : 2531 - 2536
12345